Unveiling the actual cost of Schizophrenia: An Activity-Based Costing (ABC) approach.
activity-based costing
cost of Schizophrenia
public mental health services
Journal
The International journal of health planning and management
ISSN: 1099-1751
Titre abrégé: Int J Health Plann Manage
Pays: England
ID NLM: 8605825
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
revised:
07
12
2021
received:
26
11
2020
accepted:
09
12
2021
pubmed:
24
12
2021
medline:
18
5
2022
entrez:
23
12
2021
Statut:
ppublish
Résumé
Despite its relatively low lifetime prevalence, the health, social, and economic burden of Schizophrenia is very significant. In the last 10 years, several studies have analysed the economic burden of Schizophrenia, even if there is a lack of research that has considered the actual cost for the community as the result of each event in the patient's history. The present study aims to cover this gap by proposing a novel model to evaluate better the cost of Schizophrenia with real data from medical records. We applied (i) a 'real life' analysis of medical database to capture each event of the clinical history and healthcare that could have an economic impact; and (ii) a novel Activity-Based Costing model to quantify the overall annual economic burden of a patient with Schizophrenia treated by public mental health services. We carried out the study with 523 patients with a diagnosis of Schizophrenia in the Department of Mental Health of Bari, in the South of Italy. Our results reveal an overall cost of €41.290 per patient with Schizophrenia per year. Almost half of the cost is due to rehabilitation. The second most important factor is instead related to disability and loss of productivity. We believe that the present approach represents the most effective method to properly estimate actual costs when real-life data are available compared with other studies mainly based on prevalence-based approaches.
Sections du résumé
BACKGROUND
BACKGROUND
Despite its relatively low lifetime prevalence, the health, social, and economic burden of Schizophrenia is very significant. In the last 10 years, several studies have analysed the economic burden of Schizophrenia, even if there is a lack of research that has considered the actual cost for the community as the result of each event in the patient's history.
OBJECTIVE
OBJECTIVE
The present study aims to cover this gap by proposing a novel model to evaluate better the cost of Schizophrenia with real data from medical records.
METHODS
METHODS
We applied (i) a 'real life' analysis of medical database to capture each event of the clinical history and healthcare that could have an economic impact; and (ii) a novel Activity-Based Costing model to quantify the overall annual economic burden of a patient with Schizophrenia treated by public mental health services. We carried out the study with 523 patients with a diagnosis of Schizophrenia in the Department of Mental Health of Bari, in the South of Italy.
RESULTS
RESULTS
Our results reveal an overall cost of €41.290 per patient with Schizophrenia per year. Almost half of the cost is due to rehabilitation. The second most important factor is instead related to disability and loss of productivity.
CONCLUSIONS
CONCLUSIONS
We believe that the present approach represents the most effective method to properly estimate actual costs when real-life data are available compared with other studies mainly based on prevalence-based approaches.
Types de publication
Journal Article
Langues
eng
Pagination
1366-1380Subventions
Organisme : Otsuka Pharmaceutical Italy Srl
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
American Psychiatric Association. Schizophrenia Spectrum and Other Psychotic Disorders. Diagnostic Stat Man Ment Disord. American Psychiatric Association; 2013.
NIMH » Schizophrenia [Internet]. [cited 2020 May 17]. https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml
Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005:0413-0433.
Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull [Internet]. 2008;34:173-180. 2007/06/19. Oxford University Press; https://pubmed.ncbi.nlm.nih.gov/17578893
Phanthunane P, Vos T, Whiteford H, Bertram M, Udomratn P. Schizophrenia in Thailand: prevalence and burden of disease. Popul Health Metr BioMed Central. 2010;8:24.
Jin H, Mosweu I. The societal cost of Schizophrenia: a systematic review. Pharmacoeconomics. 2017;35:25-42. Springer International Publishing.
Marcellusi A, Fabiano G, Viti R, et al. Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis. BMJ Open. 2018;8. BMJ Publishing Group.
Papa A, Mital M, Pisano P, Del Giudice M. E-health and wellbeing monitoring using smart healthcare devices: an empirical investigation. Technol Forecast Soc Change. 2020:153:119226. Elsevier Inc.
Orlando B, Ballestra LV, Magni D, Ciampi F. Open innovation and patenting activity in health care. J Intellect Cap. 2021;22:384-402. Emerald Group Holdings Ltd.
Scuotto V, Del Giudice M, Garcia-Perez A, Orlando B, Ciampi F. A spill over effect of entrepreneurial orientation on technological innovativeness: an outlook of universities and research based spin offs. J Technol Transf. 2020;45:1634-1654. Springer.
Chong HY, Teoh SL, Wu DBC, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357-373. Dove Medical Press Ltd.
Kovács G, Almási T, Millier A, et al. Direct healthcare cost of schizophrenia - European overview. Eur Psychiatry. 2018; 48:79-92. Elsevier Masson SAS.
Fasseeh A, Németh B, Molnár A, et al. A systematic review of the indirect costs of schizophrenia in Europe. Eur J Public Health [Internet]. 2018;28:1043-1049. Oxford University Press. https://pubmed.ncbi.nlm.nih.gov/30395217
Andrews G, Sanderson K, Corry J, Issakidis C, Lapsley H. Cost-effectiveness of current and optimal treatment for schizophrenia. Br J Psychiatry. 2003;183:427-435.
Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry. 1994;165:18-21. Royal College of Psychiatrists.
Teoh SL, Chong HY, Aziz SA, et al. The economic burden of schizophrenia in Malaysia. Neuropsychiatr Dis Treat. 2017;13:1979-1987. Dove Medical Press Ltd.
Kleine-Budde K, Touil E, Moock J, Bramesfeld A, Kawohl W, Rössler W. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord. 2014;16:337-353. Blackwell Munksgaard.
Wimo A, Jönsson L, Dementia BW, 2010 undefined. Health economic aspects of dementia. books.google.com [Internet]. [cited 2020 May 17]. https://books.google.it/books?hl=en&lr=&id=j7A0DgAAQBAJ&oi=fnd&pg=PA371&dq=16)+Wimo+A.,+Jonsson+L,+Gustavsson+A.+Health+economic+aspects+of+dementia.&ots=AgH5Crk4zz&sig=z3oi0uMKrBpRwayv1A-sPYp1Xto
Opoku-Boateng YN, Kretchy IA, Aryeetey GC, et al. Economic cost and quality of life of family caregivers of schizophrenic patients attending psychiatric hospitals in Ghana. BMC Health Serv Res. 2017;17:39-50. BioMed Central Ltd.
Behan C, Kennelly B, O’Callaghan E. The economic cost of schizophrenia in Ireland: a cost of illness study. Ir J Psychol Med [Internet]. 2008;25:80-87. College of Psychiatry of Ireland. [cited 2020 Sep 6] https://pubmed.ncbi.nlm.nih.gov/30282214/
Zeidler J, Slawik L, Fleischmann J, Greiner W. The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. Health Econ Rev [Internet]. 2012;2:1-8. Springer Verlag. [cited 2020 Sep 6]; https://pubmed.ncbi.nlm.nih.gov/22828440/
Evensen S, Wisløff T, Lystad JU, Bull H, Ueland T, Falkum E. Prevalence, employment rate, and cost of schizophrenia in a high-income welfare society: a population-based study using comprehensive health and welfare registers. Schizophr Bull [Internet]. 2016;42:476-483. Oxford University Press. [cited 2020 Sep 6]; https://pubmed.ncbi.nlm.nih.gov/26433216/
Kleine-Budde K, Touil E, Moock J, Bramesfeld A, Kawohl W, Rössler W. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord. 2014;16:337-353.
McGuire T, Wells KB, Bruce ML, et al. Burden of illness. Ment Health Serv Res. 2002;4.
Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77:764-771. Physicians Postgraduate Press Inc.
Latorre V, Papazacharias A, Lorusso M, et al. Improving the “real life” management of schizophrenia spectrum disorders by LAI antipsychotics: a one-year mirror-image retrospective study in community mental health services. In: Lu K, ed. PLoS One [Internet]. Public Library of Science; 2020. [cited 2020 Sep 6];15:e0230051. https://dx.plos.org/10.1371/journal.pone.0230051
Kaplan RS, William J, Bruns. Accounting and Management: Field Study Perspectives - Book - Harvard Business School [Internet]. Harvard Business School Press; 1987. [cited 2020 Sep 6]. https://www.hbs.edu/faculty/Pages/item.aspx?num=8849
Drucker P. Management Challenges for the 21st Century (Google eBook) [Internet]. Harper Business; 2012. [cited 2020 Sep 6]. https://www.harpercollins.com/products/management-challenges-for-the-21st-century-peter-f-drucker?variant=32207433302050
Claesson B, Edgren L. Activity-based costing in outpatient Psychiatry. Nord J Nurs Res [Internet]. 2001;21:42-45. SAGE Publications. [cited 2020 Sep 6]; http://journals.sagepub.com/doi/10.1177/010740830102100408
Moreno K. Adaptation of activity-based-costing (ABC) to calculate unit costs in Mental Health Care in Spain. Eur J Psychiatry. 2007;21:117-123. University of Zaragoza.
van Rensburg ABRJ, Jassat W. Acute mental health care according to recent mental health legislation Part II. Activity-based costing. Afr J Psychiatry (South Africa). 2011;14:23-29.
El Alaoui S, Lindefors N. Combining time-driven activity-based costing with clinical outcome in cost-effectiveness analysis to measure value in treatment of depression. PLoS One [Internet]. 2016;11. Public Library of Science. [cited 2020 Sep 6]; https://pubmed.ncbi.nlm.nih.gov/27798655/
Italian Health Care Ministry. Rapporto sulla salute mentale [Internet]. [cited 2020 Sep 6]. http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=5014&area=salutementale&menu=vuoto
Buchanan JM, Stubblebine WC. Externality. Economica. 1962;29.
Jacobsson F, Carstensen J, Borgquist L. Caring externalities in health economic evaluation: how are they related to severity of illness? Health Policy (New York). Elsevier. 2005;73:172-182.
Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry [Internet]. 2021;8:387-404. Elsevier Ltd. [cited 2021 Jul 6]; https://pubmed.ncbi.nlm.nih.gov/33862018/
Adelle C, Weiland S. Policy assessment: the state of the art. Impact Assess Proj Apprais. 2012;30.
Impact Assessment Toolkit version 2.0. http//www.bis.gov.uk/ia-toolkit2001.
Nove A, Cometto G, Campbell J. Assessing the health workforce implications of health policy and programming: how a review of grey literature informed the development of a new impact assessment tool. Hum Resour Health. 2017;15:1-10.
Wimo A, Jönsson L, Bond J, Prince M, Winblad B. The worldwide economic impact of dementia 2010. Alzheimer’s Dement. 2013;9:1-11.